Can severe essential hypertension raise BNP levels resulting in a misdiagnosis of heart failure?;Může závažná esenciální hypertenze způsobit vzestup BNP vedoucí k falešné diagnóze srdečního selhání?

Cor et Vasa

Volumn 48, Issue 2, 2006, Pages 48-54

  Jakubík, Peter ^a   Janota, Tomáš ^a   Wichterle, Dan ^a   Widimský, Jiří ^a   Benáková, Hana ^a   Zelinka, Tomáš ^a   Hradec, Jaromír ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

BNP; Essential hypertension; Heart failure; Left ventricular hypertrophy

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ERROR; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE SEPTUM; HEART VENTRICLE WALL; HUMAN; IMMUNOFLUORESCENCE TEST; INDIVIDUALITY; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL;

EID: 33644538591     PISSN: 00108650     EISSN: None     Source Type: Journal    
DOI: 10.33678/cor.2006.021     Document Type: Article

References (33)

1. Fonseca C, Oliveira AG, Mota T, et al. Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care. Eur J Heart Fail 2004;6:813-22.
2. Niederle P a kol. Echokardiografie. 1. díl. Praha: Triton, 2002:146-51, 256-61.
3. Maisel A, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001;141:367-74.
4. Clerico A, Lervasi G, Del Chicca MG, et al. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrinol Invest 1998;87:170-9.
5. Morrison K, Harrison A, Krishnaswamy MD, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
6. Davidson NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31.
7. Stein B, Levin R. Natriuretic peptides: physiological, therapeutical potential, and risk stratification in ischaemic heart disease. Am Heart J 1998;135:914-23.
8. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004;6:281-7.
9. Wu AHB, Harrison A, Maisel AS. Reduced readmission rate for alterning diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. Eur J Heart Fail 2004;6:309-12.
10. ESC Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2005;26:1115-40.
11. Raymond I, Groenning BA, Hildebrandt PR, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51.
12. Kohno M, Yasunari K, Yokokawa K, et al. Plasma brain natriuretic peptide during ergometric exercise in hypertensive patients with left ventricular hypertrophy. Metabolism 1996;45:1326-9.
13. Hama N, Itoh H, Shirakami G, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995;92:1558-64.
14. Altintop L, Yardan T, Cander B, Findik S, Yilmaz O. An increase of BNP levels in massive pulmonary embolism and the reduction in response to the acute treatment. Resuscitation 2005;65:225-9.
15. Cullough PA, Kuncheria J, Vandana SM. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med 2004;5:16-25.
16. Deary AJ, Schumann AL, Murfet H, et al. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension. Clin Sci (Lond) 2002;103:493-9.
17. Missouris CG, Grouzmann E, Buckley MG, Barron J, MacGregor GA, Singer DR. How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. Clin Sci (Lond.) 1998;94:591-9.
18. Suzuki M, Hamada M, Yamamoto K, Kazatani Y, Hiwada K. Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events. Hypertens Res 2002;25:669-76.
19. Olsen MH, Wachtell K, Tuxen Ch, et al. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.
20. Cheung BM, Brown MJ. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension. J Hypertens 1994;12:449-54.
21. Tanaka M, Ishizaka Y, Ishiyama Y, et al. Excercise - induced secretion of BNP in essential hypertension and normal subjects. Hypertens Res 1995;18:159-66.
22. Buckley MG, Markandu ND, Miller MA, Sagnella GA, MacGregor GA. Plasma concentrations and comparisons of brain and atrial natriuretic peptide in normal subjects and in patients with essential hypertension. J Hum Hypertens 1993;7:245-50.
23. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92:29-34.
24. Hildebrandt P, Bosen M, Michael O, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6:313-7.
25. Almeida P, Azevedo A, Rodrigues R, et al. B-type natriuretic peptide and left ventricular hypertrophy in hypertensive patients. Rev Port Cardiol 2003;22:327-36.
26. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28:22-30.
27. Talwar S, Siebenhofer A, Williams B, et al. Influence of hypertension, left ventricular hypertrophy and left ventricular systolic dysfunction on plasma N-terminal pro-BNP. Heart 2000;83:278-82.
28. Fontes RG, Kater CE, Biglieri EG, Irony I. Reassessment of the predictive value of the postural stimulation test in primary aldosteronism. N Engl J Med 1998;339:1828-34.
29. Hambling C, Jung RT, Gunn A, Browning MC, Bartlett WA. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf.) 1992:36:499-503.
30. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 1971;128:380-6.
31. Janota T, Benáková H, Jakubík P, Hradec J, Zima T. Statimové stanovování BNP v diagnostice srdečního selhání a jeho limitace. Cor Vasa 2003;45:S36.
32. Sahn DJ, DeMaria A. Kisslo J, et al. Recommendations regarding quantitation in M-mode echocardiography: resultes of a survey of echocardiography measurements. Circulation 1978;75:1072-83.
33. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography: anatomic validation, standardization, and comparison to other methods. Hypertension 1987; (Suppl II):19-26.